Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
roche
6
×
biotech
boston blog main
boston top stories
san francisco top stories
clinical trials
fda
san francisco blog main
blueprint medicines
boston
cancer
deals
europe top stories
genentech
indiana blog main
indiana top stories
national
new york top stories
avapritinib
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drug prices
drugs
eli lilly
europe blog main
gene therapy
investing
medullary thyroid cancer
new york blog main
non-small cell lung cancer
novartis
pralsetinib
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
What
fda
6
×
drug
approval
cancer
medicine
roche
therapy
approved
blueprint
genetic
medicines
new
ret
second
address
ahead
approves
asco
atrophy
betting
billion
bio
biopharma
branded
candidate
carries
certain
choices
commissioner
consumers
costly
counterweight
currently
daily
deal
deeper
designed
dna
drugs
duchenne
Language
unset
Current search:
roche
×
fda
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues